Home/Filings/4/0001225208-25-002401
4//SEC Filing

LANKLER DOUGLAS M 4

Accession 0001225208-25-002401

CIK 0000078003other

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 7:05 PM ET

Size

17.5 KB

Accession

0001225208-25-002401

Insider Transaction Report

Form 4
Period: 2025-02-22
LANKLER DOUGLAS M
Senior Vice President
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-22$30.17/sh+85,824$2,589,310232,775 total
  • Exercise/Conversion

    Stock Appreciation Rights

    2025-02-2285,8240 total
    Exercise: $30.17From: 2025-02-22Exp: 2025-02-22Common Stock (85,824 underlying)
  • Tax Payment

    Common Stock

    2025-02-22$26.08/sh76,565$1,996,815152,876 total
  • Tax Payment

    Common Stock

    2025-02-22$26.30/sh3,334$87,684229,441 total
Holdings
  • Common Stock

    (indirect: By Rule 16b-3 Plan)
    1,951
Footnotes (5)
  • [F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
  • [F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
  • [F3]Price is the closing price of Pfizer common stock on February 21, 2025.
  • [F4]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
  • [F5]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

Issuer

PFIZER INC

CIK 0000078003

Entity typeother

Related Parties

1
  • filerCIK 0001488270

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 7:05 PM ET
Size
17.5 KB